Device/Diagnostics Quarterly Deal-Making Statistics, Q4 2017

A look at the financing, M&A and alliance activity in October–December 2017

Device fundraising during the fourth quarter totaled $2.6 billion, making it the strongest quarter of the year. Q4 M&A activity reached $3.9 billion, higher than Q3's $3.4 billion, but still one of the lowest quarters of the year. Both fourth quarter diagnostics financings and M&As hit an all-year low of $622 million, and $2.8 million, respectively.

Quarterly Stats_1200x675

Device fundraising in Q4 2017 totaled $2.6 billion, the highest single-quarter value of the year. However, total 2017 financing for the industry declined from 2016: $8.4 billion in 2017 compared with $8.9 billion from the previous year. This wasn't a significant decline, but a decline nonetheless. One major difference in 2017 was notably less money coming in from IPOs – in 2016, companies raised $2 billion through IPOs, exponentially more than 2017's $175 million (but approximately $1.8 billion in 2016 was from a single IPO transaction, by ConvaTec Inc.[See Deal]). In 2017, debt offerings gradually grew in value, reaching well over $1 billion in the final two quarters. In contrast, there was a notable decline in early-stage financings, which totaled $990 million in Q1, but slowed down to just $152 million in Q4, although the majority of the Q1 figure was from Verily Life Sciences LLC's $800 million Series A round from Temasek [See Deal]. (See Exhibit 1.)

Exhibit 1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By 

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Deals In Depth: April 2025

 
• By 

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

Deals Shaping The Industry, April 2025

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during April 2025. Data courtesy of Biomedtracker.

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By 

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.